https://www.cooley.digital/references/ 

img width="426" src="https://internetstartup.vn/co-cau-phong-marketing/imager_3_183075_700.jpg">

img src="https://i.imgur.com/R4ZqQhR.jpg" alt="List Of Danish Biotech Companies" align="right" style="max-width:32% max-height:242px; width:auto; margin:0px 10px; height:auto;"> <h1>A List Of Danish Biotech Companies</h1> <p>If you're looking for reliable data on Danish biotech firms, consider using a firm like BoldData. The database of BoldData contains data from Central Business Register and Danish Chambers of Commerce. This database can help you create a winning marketing campaign to promote your biotech business. BoldData's data is regularly updated and can assist you in creating an effective and targeted campaign.

/p> <h2>Orphazyme

/h2>

p>A biopharmaceutical company that is in the late stages Orphazyme is in the process of developing a novel treatment for the neurodegenerative disease Niemann-Pick type C. The company has a lead candidate under development, called Arimoclomol. The company plans to submit a request for marketing authorization to the EMA in the second quarter of 2020.

/p> <p>The company has a long history of focusing on rare diseases. Marja Jaattela and Thomas Kirkegaard founded the company in 2010. They have been focusing their efforts on the storage disorders of lysosomes particularly.

/p> <h2>Symphogen

/h2>

p>French pharma Servier has agreed to purchase Symphogen, an Danish biotech company that has developed an antibody discovery platform to aid in cancer treatments. Servier's antibody pipeline will be strengthened with this acquisition. Since over two years, the two companies have been working in the immuno-oncology field. Servier will benefit from Symphogen's knowledge, technology, and resources.

/p> <p>Symphogen's management team is knowledgeable and diverse. Kirsten Drejer is an experienced professional in the industry with an established track record of creating an impressive pipeline and supporting the company to achieve solid financial results. The company also has assets that have positive clinical data.

/p> <h2>Galecto Biotech

/h2>

p>Galecto Biotech is a Danish biotech company that develops novel medicines to treat serious ailments. The main product they are developing is galectin-3, a protein which is involved in a myriad of inflammatory and immune reactions. The company is currently running clinical trials to treat idiopathic pulmonary fibrosis. It has partnered with Bristol-Myers Squibb and has plans to conduct additional clinical trials for fibrotic diseases.

/p> <p>Galecto Biotech's products are based on a research-based technology that targets the galectin-3 receptor. The team responsible for product development is focused on the development and commercialization of chemically-derived therapeutic drugs. But they don't stop there. The company is also launching late-stage clinical trials using its galectin modulator. This could eventually bring about a cure for asthma and nasal polyposis.

/p> <h2>Novo Nordisk

/h2>

p>The biotech firm has also succeeded in acquiring a biotech company in the U.S. in the last year, Dicerna Pharmaceuticals of Lexington. Dicerna has previously developed medicines based upon RNA interference. This is a method of shutting down genes that cause diseases.

/p> <p>The company plans to invest a total of 17 billion Danish kroner in three new manufacturing facilities. It will also expand the existing facility in Kalundborg, Denmark. These new facilities will enhance the global value chain's capacity. They will also increase the production of injectable and oral products. The new facilities will be fitted with state-of the-art production technology.

/p> <h2>Novozymes

/h2>

p>Novozymes is a Danish biotechnology company, is a specialist in industrial enzymes. The company is a leader in many markets to serve and its earnings are primarily generated in the following sectors that include bio-energy, agriculture, and household care. Novozymes was established in 1988 and is headquartered in Copenhagen in Denmark.

/p> <p>The Danish biotech company has a long history of success in product roll-out. Its predecessor, Nordisk Insulinlaboratorium, launched its first enzyme, trypsin in 1941. The enzyme was initially used to soften leather. The process of fermentation that allows enzyme production was also developed by the company. In the latter half of the 1980s, it created the first enzyme in the world to produce detergents: lipolase. This enzyme was able to improve the freshness of white bread and buns.

/p> <h2>Lilly

/h2>

p>A majority of the world's prominent biotech companies are located in Denmark. They use biotechnology to combat cancer, create vaccines, and provide other medical solutions. Oncology Venture ApS specializes in research and development in the field of cancer. AquaGreen is an Danish biotech engineering company and STipe Therapeutics are other notable companies. They harness the innate immune system to fight cancer. Acesion Pharma, a Danish biotech firm, is developing drugs for atrial fibrillation.

/p> <p>Denmark and Sweden have a long-standing history in the biotechnology and medical technology industries. They are among the top five pharmaceutical exporters in the world. Denmark also has one of the highest per capita R&D spending in the European pharmaceutical industry, which is second only to Switzerland. Furthermore, 60 percent of the pharmaceutical activities in Scandinavia are concentrated in the Medicon Valley, a Danish-Swedish cross-border cluster.

/p> <h2>Innovent

/h2>

p>Innovent Biotech recently secured exclusive rights for Eli Lilly's cancer medicines in China. The deal will allow Innovent to control the pricing as well as marketing, sales, and distribution of the drugs. Both companies will collaborate on the development and distribution of treatments for major unmet medical requirements, such as eczema or cancer.

/p> <p>Innovent has 16 potential products in its pipeline. Seven are currently in the process of clinical development. Seven also partnered with Eli Lilly to develop three Chinese cancer treatments. Ascentage is a Danish biotech company, has joined forces with Oriza Ventures, and the Chinese state-owned SDIC Fund Management.

/p> <iframe height="282" allowfullscreen="true" frameborder="0" src="https://www.youtube.com/embed/ccGs550TSjk" width="505" style="margin:0px auto; display: block;"></iframe>


トップ   編集 凍結 差分 バックアップ 添付 複製 名前変更 リロード   新規 一覧 単語検索 最終更新   ヘルプ   最終更新のRSS
Last-modified: 2022-09-16 (金) 19:13:26 (594d)